Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Chia Wei Li; Seung Oe Lim; Weiya Xia; Heng Huan Lee; Li Chuan Chan; Chu Wei Kuo; Kay Hooi Khoo; Shih Shin Chang; Jong Ho Cha; Taewan Kim; Jennifer L. Hsu; Yun Wu; Jung Mao Hsu; Hirohito Yamaguchi; Qingqing Ding; Yan Wang; Jun Yao; Cheng Chung Lee; Hsing Ju Wu; Aysegul A. Sahin; James P. Allison; Dihua Yu; Gabriel N. Hortobagyi; Mien Chie Hung

doi:10.1038/ncomms12632

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Chia Wei Li, Seung Oe Lim, Weiya Xia, Heng Huan Lee, Li Chuan Chan, Chu Wei Kuo, Kay Hooi Khoo, Shih Shin Chang, Jong Ho Cha, Taewan Kim, Jennifer L. Hsu, Yun Wu, Jung Mao Hsu, Hirohito Yamaguchi, Qingqing Ding, Yan Wang, Jun Yao, Cheng Chung Lee, Hsing Ju Wu, Aysegul A. SahinJames P. Allison, Dihua Yu, Gabriel N. Hortobagyi, Mien Chie Hung

Research output: Contribution to journal › Article › peer-review

510 Citations (Scopus)

Abstract

Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation. We show that glycogen synthase kinase 3β (GSK3β) interacts with PD-L1 and induces phosphorylation-dependent proteasome degradation of PD-L1 by β-TrCP. In-depth analysis of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3β binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3β and β-TrCP. We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3β inactivation in basal-like breast cancer. Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models. Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.

Original language	English
Article number	12632
Journal	Nature Communications
Volume	7
DOIs	https://doi.org/10.1038/ncomms12632
Publication status	Published - Aug 30 2016
Externally published	Yes

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ncomms12632

Cite this

Li, C. W., Lim, S. O., Xia, W., Lee, H. H., Chan, L. C., Kuo, C. W., Khoo, K. H., Chang, S. S., Cha, J. H., Kim, T., Hsu, J. L., Wu, Y., Hsu, J. M., Yamaguchi, H., Ding, Q., Wang, Y., Yao, J., Lee, C. C., Wu, H. J., ... Hung, M. C. (2016). Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications, 7, [12632]. https://doi.org/10.1038/ncomms12632

Li, CW, Lim, SO, Xia, W, Lee, HH, Chan, LC, Kuo, CW, Khoo, KH, Chang, SS, Cha, JH, Kim, T, Hsu, JL, Wu, Y, Hsu, JM, Yamaguchi, H, Ding, Q, Wang, Y, Yao, J, Lee, CC, Wu, HJ, Sahin, AA, Allison, JP, Yu, D, Hortobagyi, GN & Hung, MC 2016, 'Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity', Nature Communications, vol. 7, 12632. https://doi.org/10.1038/ncomms12632

@article{b3d010de4c2e4d2380e9f9257273c92e,

title = "Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity",

abstract = "Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation. We show that glycogen synthase kinase 3β (GSK3β) interacts with PD-L1 and induces phosphorylation-dependent proteasome degradation of PD-L1 by β-TrCP. In-depth analysis of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3β binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3β and β-TrCP. We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3β inactivation in basal-like breast cancer. Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models. Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.",

author = "Li, {Chia Wei} and Lim, {Seung Oe} and Weiya Xia and Lee, {Heng Huan} and Chan, {Li Chuan} and Kuo, {Chu Wei} and Khoo, {Kay Hooi} and Chang, {Shih Shin} and Cha, {Jong Ho} and Taewan Kim and Hsu, {Jennifer L.} and Yun Wu and Hsu, {Jung Mao} and Hirohito Yamaguchi and Qingqing Ding and Yan Wang and Jun Yao and Lee, {Cheng Chung} and Wu, {Hsing Ju} and Sahin, {Aysegul A.} and Allison, {James P.} and Dihua Yu and Hortobagyi, {Gabriel N.} and Hung, {Mien Chie}",

note = "Funding Information: This work was funded in part by the following: National Institutes of Health (grants R01 CA109311, PO1 CA099031 and CCSG CA016672); National Breast Cancer Foundation Inc., Breast Cancer Research Foundation (to M.-C.H. and G.N.H.); Patel Memorial Breast Cancer Endowment Fund; The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund (to M.-C.H.); Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST105-2911-I-002-302); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW105-TDU-B-212-134003); Center for Biological Pathways; Susan G. Komen for the Cure Postdoctoral Fellowship (PDF12231298 to S.-O.L.); Basic Science Research Program through the National Research Foundation of Korea funded by the Korea government (MSIP; NRF-2011-357-C00140 to S.-O.L.); the National Research Foundation of Korea (NRF) grant for the Global Core Research Center (GCRC) funded by the Korea government (MSIP; 2011-0030001 to J.-H.C.). Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = aug,

day = "30",

doi = "10.1038/ncomms12632",

language = "English",

volume = "7",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

AU - Li, Chia Wei

AU - Lim, Seung Oe

AU - Xia, Weiya

AU - Lee, Heng Huan

AU - Chan, Li Chuan

AU - Kuo, Chu Wei

AU - Khoo, Kay Hooi

AU - Chang, Shih Shin

AU - Cha, Jong Ho

AU - Kim, Taewan

AU - Hsu, Jennifer L.

AU - Wu, Yun

AU - Hsu, Jung Mao

AU - Yamaguchi, Hirohito

AU - Ding, Qingqing

AU - Wang, Yan

AU - Yao, Jun

AU - Lee, Cheng Chung

AU - Wu, Hsing Ju

AU - Sahin, Aysegul A.

AU - Allison, James P.

AU - Yu, Dihua

AU - Hortobagyi, Gabriel N.

AU - Hung, Mien Chie

N1 - Funding Information: This work was funded in part by the following: National Institutes of Health (grants R01 CA109311, PO1 CA099031 and CCSG CA016672); National Breast Cancer Foundation Inc., Breast Cancer Research Foundation (to M.-C.H. and G.N.H.); Patel Memorial Breast Cancer Endowment Fund; The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund (to M.-C.H.); Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST105-2911-I-002-302); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW105-TDU-B-212-134003); Center for Biological Pathways; Susan G. Komen for the Cure Postdoctoral Fellowship (PDF12231298 to S.-O.L.); Basic Science Research Program through the National Research Foundation of Korea funded by the Korea government (MSIP; NRF-2011-357-C00140 to S.-O.L.); the National Research Foundation of Korea (NRF) grant for the Global Core Research Center (GCRC) funded by the Korea government (MSIP; 2011-0030001 to J.-H.C.). Publisher Copyright: © 2016 The Author(s).

PY - 2016/8/30

Y1 - 2016/8/30

N2 - Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation. We show that glycogen synthase kinase 3β (GSK3β) interacts with PD-L1 and induces phosphorylation-dependent proteasome degradation of PD-L1 by β-TrCP. In-depth analysis of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3β binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3β and β-TrCP. We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3β inactivation in basal-like breast cancer. Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models. Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.

AB - Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation. We show that glycogen synthase kinase 3β (GSK3β) interacts with PD-L1 and induces phosphorylation-dependent proteasome degradation of PD-L1 by β-TrCP. In-depth analysis of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3β binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3β and β-TrCP. We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3β inactivation in basal-like breast cancer. Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models. Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84984911573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984911573&partnerID=8YFLogxK

U2 - 10.1038/ncomms12632

DO - 10.1038/ncomms12632

M3 - Article

C2 - 27572267

AN - SCOPUS:84984911573

SN - 2041-1723

VL - 7

JO - Nature Communications

JF - Nature Communications

M1 - 12632

ER -

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this